Trastuzumab deruxtecan
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd) . Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
Product Specifications
CAS Number
1826843-81-5
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
Approximately 45.42 kDa
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Antibody-Drug Conjugates (ADCs)
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
034596-APC 200 µL
DFFB, NT (DFFB, CAD, DFF2, DFF40, DNA fragmentation factor subunit beta, Caspase-activated deoxyribonuclease, Caspase-activated nuclease, DNA fragmentation factor 40kD subunit) (APC) discontinued
Ask
View Details 124987 100 µg
CHST3 (Carbohydrate sulfotransferase 3, Chondroitin 6-O-sulfotransferase 1, Chondroitin 6-sulfotransferase, Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 0)
Ask
View Details 